Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
20083.9k citationsDavid N. Gilbert, Brad Spellberg et al.Clinical Infectious Diseasesprofile →
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
This map shows the geographic impact of John Bartlett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Bartlett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Bartlett more than expected).
This network shows the impact of papers produced by John Bartlett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Bartlett. The network helps show where John Bartlett may publish in the future.
Co-authorship network of co-authors of John Bartlett
This figure shows the co-authorship network connecting the top 25 collaborators of John Bartlett.
A scholar is included among the top collaborators of John Bartlett based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with John Bartlett. John Bartlett is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Bartlett, John. (2004). Persistent colonization by haemophilus influenzae in chronic obstructive pulmonary disease. Infectious Diseases in Clinical Practice. 12(6). 377–378.20 indexed citations
5.
Bartlett, John. (2004). Updated guidelines for use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Infectious Diseases in Clinical Practice. 12(3). 182–183.18 indexed citations
6.
Bartlett, John. (2004). The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for helicobacter pylori infections. Infectious Diseases in Clinical Practice. 12(2).19 indexed citations
7.
Bartlett, John. (2004). Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). Infectious Diseases in Clinical Practice. 12(4).
8.
Bartlett, John. (2004). No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomized, double-blind, placebo-controlled trial. Infectious Diseases in Clinical Practice. 12(4).6 indexed citations
9.
Bartlett, John. (2004). Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: A randomized trial. Infectious Diseases in Clinical Practice. 12(2).2 indexed citations
10.
Bartlett, John. (2004). Peginterferon alfa-2a Plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-Co-infected persons. Infectious Diseases in Clinical Practice. 12(6). 367–368.6 indexed citations
11.
Bartlett, John. (2004). Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naïve adults with advanced HIV infection. Infectious Diseases in Clinical Practice. 12(3). 198–199.1 indexed citations
12.
Bartlett, John. (2004). Weight loss and wasting in patients infected with human immunodeficiency virus. Infectious Diseases in Clinical Practice. 12(2).1 indexed citations
13.
Bartlett, John. (2004). Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study. Infectious Diseases in Clinical Practice. 12(4).11 indexed citations
14.
Bartlett, John. (2004). Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Infectious Diseases in Clinical Practice. 12(4). 248–249.1 indexed citations
15.
Bartlett, John. (2004). CDC/HRSA/NIH/HIVMA of the IDSA recommendations for incorporating HIV prevention into the medical care of HIV-infected persons. Infectious Diseases in Clinical Practice. 12(2). 126–127.1 indexed citations
16.
Bartlett, John. (2004). Treatment for adult HIV infection: 2004 recommendations of the international AIDS society-USA panel. Infectious Diseases in Clinical Practice. 12(6). 362–363.17 indexed citations
17.
Bartlett, John. (2004). Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. Infectious Diseases in Clinical Practice. 12(4).1 indexed citations
18.
Bartlett, John. (2004). Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Infectious Diseases in Clinical Practice. 12(6). 368–369.1 indexed citations
19.
Bartlett, John. (2004). Absolute CD4 versus CD4 percentage for predicting the risk of opportunistic illness in HIV infection. Infectious Diseases in Clinical Practice. 12(6).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.